{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:28:07Z","timestamp":1790195287179,"version":"4.1.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The widespread clinical use of immune checkpoint inhibitors (ICIs) in oncology has been accompanied by an increased incidence of immune-related adverse events (irAEs). When ICIs are combined with other medications, the risk of drug-induced liver injury (DILI) and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) may be amplified. Moxifloxacin, a fluoroquinolone antibiotic known to cause hepatic injury and cutaneous adverse reactions, is an uncommon culprit in the setting of prior ICI therapy but warrants vigilance for its potential to precipitate acute DILI and TEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a case of a 58-year-old man with lung adenocarcinoma who achieved a major pathological response after neoadjuvant tislelizumab combined with carboplatin and docetaxel. Postoperatively, he developed severe pneumonia and was treated with moxifloxacin and vancomycin. He subsequently developed severe DILI and TEN. Causality assessment implicated moxifloxacin as the principal offending agent, with a RUCAM score of 9 (probable) and an ALDEN score of 5 (probable). In addition, we conducted a systematic review of 28 published cases of concurrent DILI and SJS\/TEN to characterize drug classes and clinical features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten days after initiation of moxifloxacin, the patient developed synchronous DILI and TEN, suggesting that prior immunotherapy may have lowered the threshold for immune tolerance and amplified T cell\u2013mediated, drug-induced immune responses. At 23 months postoperatively, no tumor recurrence was observed. Our systematic review identified a relatively high representation of fluoroquinolones among cases of concurrent DILI and SJS\/TEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prior exposure to ICIs may enhance drug-triggered immune responses and thereby increase the risk of DILI and SJS\/TEN. Clinicians should exercise caution when prescribing fluoroquinolones to patients who are receiving or have recently received immunotherapy and should intensify surveillance for drug-related adverse reactions. Future studies are needed to elucidate the immunologic synergism between ICIs and concomitant medications in order to optimize clinical management and risk prediction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1753434","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:52:22Z","timestamp":1774421542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Concurrent moxifloxacin-induced liver injury and toxic epidermal necrolysis after immune checkpoint inhibition: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiangsheng","family":"Li","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University","place":["Bengbu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University","place":["Bengbu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University","place":["Bengbu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University","place":["Bengbu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University","place":["Bengbu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University","place":["Bengbu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Third People's Hospital of Bengbu Affiliated to Bengbu Medical University","place":["Bengbu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217241","article-title":"Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions","volume":"604","author":"Gang","year":"2024","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12916-025-03919-0","article-title":"High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study","volume":"23","author":"Wicherski","year":"2025","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013373435","article-title":"Adverse reactions to fluoroquinolones. an overview on mechanistic aspects","volume":"8","author":"De Sarro","year":"2001","journal-title":"Curr Med Chem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13256-024-04574-4","article-title":"Case analysis of hepatotoxicity caused by vancomycin","volume":"18","author":"Wu","year":"2024","journal-title":"J Med Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111799","article-title":"New advances in the study of PD-1\/PD-L1 inhibitors-induced liver injury","volume":"131","author":"Yue","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(85)80012-8","article-title":"Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid \"pulse therapy","volume":"12","author":"Sherertz","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199106030-00007","article-title":"A case of Stevens-Johnson syndrome, cholestatic hepatitis and haemolytic anaemia associated with use of mefenamic acid","volume":"6","author":"Chan","year":"1991","journal-title":"Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18104","article-title":"Amoxicillin\/clavulanate-associated hepatic failure with progression to Stevens-Johnson syndrome","volume":"33","author":"Limauro","year":"1999","journal-title":"Ann Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02338.x","article-title":"Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases","volume":"16","author":"Lin","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.4.474","article-title":"Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy","volume":"162","author":"Masi\u00e1","year":"2002","journal-title":"Arch Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1537","article-title":"Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure","volume":"140","author":"Nori","year":"2004","journal-title":"Arch Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2005.tb00817.x","article-title":"A case of histopathologically typical toxic epidermal necrolysis despite no visible blisters or erosive lesions","volume":"32","author":"Kakeda","year":"2005","journal-title":"J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-007-1367-9","article-title":"Letaler Ausgang einer Chemotherapie mit Docetaxel. Akutes Leberversagen mit begleitendem Erythema exsudativum multiforme majus [Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major","volume":"46","author":"Ohlmann","year":"2007","journal-title":"Urologe A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0399-8320(07)78331-8","article-title":"H\u00e9patite cholestatique s\u00e9v\u00e8re associ\u00e9e \u00e0 un syndrome de Stevens-Johnson apr\u00e8s la prise d'ibuprof\u00e8ne [Severe cholestatic hepatitis associated with Stevens-Johnson syndrome after taking ibuprofen","volume":"31","author":"Elkrief","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.4697","article-title":"Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus","volume":"14","author":"Okan","year":"2008","journal-title":"World J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1130-6343(09)71002-5","article-title":"S\u00edndrome de Stevens-Johnson y hepatitis t\u00f3xica por esomeprazol [Stevens-Johnson syndrome and toxic hepatitis due to esomeprazole","volume":"33","author":"Dom\u00ednguez-Le\u00f1ero","year":"2009","journal-title":"Farm Hosp"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03153.x","article-title":"Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation","volume":"10","author":"Jao","year":"2010","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2012.1870","article-title":"Toxic epidermal necrolysis complicated by sepsis, haemophagocytic syndrome, and severe liver dysfunction associated with elevated interleukin-10 production","volume":"22","author":"Yamaoka","year":"2012","journal-title":"Eur J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311308010011","article-title":"Nevirapine and\/or co-trimoxazole induced Stevens Johnson syndrome in HIV infected patient--a case report","volume":"8","author":"Patel","year":"2013","journal-title":"Curr Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.131096","article-title":"Nevirapine induced toxic epidermal necrolysis and non-Hodgkin lymphoma in a Human Immunodeficiency Virus positive patient","volume":"5","author":"Budamakuntla","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.2.180","article-title":"Liver dysfunction induced by systemic hypersensitivity reaction to lamotrigine: case report","volume":"21","author":"Im","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2174\/1574886309666140827122735","article-title":"Paracetamol-induced Stevens Johnson syndrome and cholestatic hepatitis","volume":"10","author":"Slim","year":"2015","journal-title":"Curr Drug Saf"},{"key":"B25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/jgh.12849","article-title":"Education and imaging. Hepatology: Rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation","volume":"30","author":"Harimoto","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12760","article-title":"Fluoxetine-induced Stevens-Johnson syndrome and liver injury","volume":"44","author":"Agrawal","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000598396.71372.e7","article-title":"2216\u2003Toxic epidermal necrolysis and drug-induced liver injury secondary to oseltamivir","volume":"114","author":"Shaikh","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15963","article-title":"A pediatric case of Stevens-Johnson syndrome with acute liver failure, resulting in liver transplantation","volume":"48","author":"Totsuka","year":"2021","journal-title":"J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.672233","article-title":"Case report: stevens-johnson syndrome and hepatotoxicity induced by osimertinib sequential to pembrolizumab in a patient with EGFR-mutated lung adenocarcinoma","volume":"12","author":"Gianni","year":"2021","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/tp-21-8","article-title":"Ibuprofen induced Stevens-Johnson syndrome and liver injury in children: a case report","volume":"10","author":"Gui","year":"2021","journal-title":"Transl Pediatr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211033196","article-title":"Warfarin-induced Stevens-Johnson syndrome with severe liver injury","volume":"49","author":"Xiong","year":"2021","journal-title":"J Int Med Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.975754","article-title":"Case report: Development of vanishing bile duct syndrome in Stevens-Johnson syndrome complicated by hemophagocytic lymphohistiocytosis","volume":"9","author":"Lin","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001047076.23057.b0","article-title":"S4427\u2003Drug-induced autoimmune-like hepatitis and stevens johnsons syndrome secondary to levetiracetam","volume":"119","author":"Caviness","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1662795","article-title":"High serum unconjugated bilirubin levels following successful treatment of antiepileptic drug-induced bullosa epidermolysis: a case report and review of the literature","volume":"12","author":"Cheng","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2174\/2772270817666230821102441","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis: an overview of diagnosis, therapy options and prognosis of patients","volume":"17","author":"Garg","year":"2023","journal-title":"Recent Adv Inflammation Allergy Drug Discov"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1111\/all.70037","article-title":"Diagnosis of quinolone hypersensitivity: an EAACI position paper","volume":"80","author":"Gelincik","year":"2025","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11882-017-0725-y","article-title":"Update on quinolone allergy","volume":"17","author":"Do\u00f1a","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060675","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis: analysis of the Russian database of spontaneous reports","volume":"17","author":"Zyryanov","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1527051","article-title":"Toxic epidermal necrolysis induced by moxifloxacin and exacerbated by clindamycin in an elderly patient: A case report","volume":"12","author":"Wang","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2222.2006.02402.x","article-title":"T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity","volume":"36","author":"Schmid","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy","volume":"3","author":"Liu","year":"2024","journal-title":"Cell Insight"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/toxsci\/kfae046","article-title":"Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis","volume":"200","author":"Pallardy","year":"2024","journal-title":"Toxicol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-01019-7","article-title":"Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management","volume":"22","author":"Triantafyllou","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15896","article-title":"Postoperative systemic inflammatory dysregulation and corticosteroids: a narrative review","volume":"78","author":"Bain","year":"2023","journal-title":"Anaesthesia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s40001-025-02664-7","article-title":"Recent developments in the research of Stevens-Johnson syndrome and toxic epidermal necrolysis: pathogenesis, diagnosis and treatment","volume":"30","author":"Yao","year":"2025","journal-title":"Eur J Med Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100738","article-title":"Clinical aspects of severe cutaneous adverse reactions caused by beta-lactam antibiotics: A study from the Korea SCAR registry","volume":"16","author":"Kim","year":"2023","journal-title":"World Allergy Organ J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:52:25Z","timestamp":1774421545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2026.1753434"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1753434","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"article-number":"1753434"}}